scholarly journals Evaluation of the efficacy and tolerability of combination therapy for lower urinary tract symptoms in patients with chronic prostatitis and benign prostatic hyperplasia

2021 ◽  
Vol 14 (2) ◽  
pp. 37-42
Author(s):  
I.V. Vinogradov ◽  
◽  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Chronic Prostatitis ◽  
Lower Urinary Tract ◽  
Combined Therapy ◽  
Prostatic Hyperplasia ◽  
Urine Flow ◽  
Group I ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Introduction. Chronic prostatitis (CP) is one of the most common urological diseases; CP often accompanies benign prostatic hyperplasia (BPH). Quite often in patients with CP, obstructive, irritative and urethral symptoms are detected. However, there is simply no effective therapy for CP. Despite the lack of data on the proven effectiveness of herbal medicine in international clinical trials, this treatment for CP and BPH remains popular. Aim. To study clinical efficacy and safety of CHINCH herbal drug in treatment of patients with CP and BPH. Materials and methods. 820 men from 13 clinical centers of the Russian Federation with lower urinary tract symptoms associated with CP and BPH were included in the study. The patients were divided into 2 groups. Group I included 423 patients who were administered a complex therapy with Tamsulosin (0.4 mg, 1 capsule once a day for 2 months) and CHINCH (2 capsules 2 times a day for 2 months). Group II consisted of 397 patients who had only Tamsulosin (0.4 mg, 1 capsule once a day for 2 months). Results. According to uroflowmetry, the patients from the group with combined therapy showed significantly better average values of the maximum urine flow rate (Qmax) at the end of 2 months of the therapy, than the initial values in the group, as well as the values of the monotherapy group (p<0.05). All patients noted an increase in the urine flow rate after a month of taking drugs with an increase in the effect by the end of the program. All patients who were included in the observational program, marked an improvement in the quality of life (QoL). The QоL value in the group I became significantly higher (p <0.05) compared with the initial and intermediate values, as well as with the same values in the monotherapy group. All patients noted that the prescribed therapy was well tolerated. Discussion. The study showed, that both subjective and objective criteria for assessing the disease course improved in patients using our approach of complex therapy for lower urinary tract symptoms, associated with CP and BPH (CHINCH in combination with Tamsulosin). These results indicate that the use of herbal therapy in combination with basic therapy with Tamsulosin is an effective and safe treatment method for lower urinary tract symptoms, caused by CP and BPH. Our results are consistent with the data of other researchers. Conclusions. Combined therapy with an alpha-adrenergic blocker in combination with CHINCH, compared with monotherapy, can help to achieve a faster and more significant result in the relief of lower urinary tract symptoms caused by CP and BPH. The combined therapy allows to achieve a higher level of Qmax, IPSS and QOL values within a month, and by the end of the second month - to enhance this effect. The use of CHINCH is not accompanied by adverse effects and can be administered for a long time to relieve lower urinary tract symptoms in patients with CP and BPH.

scholarly journals Efficiency of sildanefil monotherapy in benign prostatic hyperplasia

2016 ◽  
Vol 69 (11-12) ◽  
pp. 379-383
Author(s):  
Dragan Grbic ◽  
Sasa Vojinov ◽  
Dimitrije Jeremic ◽  
Ivan Levakov ◽  
Senjin Djozic ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Symptom Score ◽  
Lower Urinary Tract Symptoms ◽  
International Prostate Symptom Score ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Urine Flow ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Introduction. High incidences of benign prostatic hyperplasia and lower urinary tract symptoms have a high socioeconomic importance. There are several published studies which have proved the efficiency of phosphodiesterase type 5 inhibitors in treatment of benign prostatic hyperplasia and lower urinary tract symptoms. However, more studies are needed to make this therapy the standard option for treating benign prostatic hyperplasia and lower urinary tract symptoms. This study was aimed at exploring changes in International Prostate Symptom Score, post voiding residuum and maximal urine flow in benign prostatic hyperplasia and lower urinary tract symptoms patients treated by sildenafil for benign prostatic hyperplasia and lower urinary tract symptoms. Material and Methods. This study, which was conducted as a prospective, controlled, opened, randomized study, included 30 patients with benign prostatic hyperplasia and lower urinary tract symptoms. Research was conducted at the Department of Urology, Clinical Center of Vojvodina (November 2011 till November 2012). The inclusion criteria were as following: >45 years of age, International Prostate Symptom Score >3, prostatic specific antigen <10, normal urinalysis. The patients were periodically tested for International Prostate Symptom Score, maximal urine flow, and post voiding residuum. Results. Statistically significant changes were found in all parameters: mean International Prostate Symptom Score value improved from 12.8 to 8.6 (32.8% change), mean post voiding residuum value decreased from 49.4 ml to 40.2 ml (18.6% change), mean maximal urine flow value increased from 11.8 ml/s to 12.8 ml/s (8.5% change). Conclusion. Treatment of benign prostatic hyperplasia and lower urinary tract symptoms with a continuous low dose of sildenafil seems to be a good treatment choice for the patients with mild to moderate benign prostatic hyperplasia and lower urinary tract symptoms, especially in the patients with concomitant erectile dysfunction. The authors are aware that their study is limited by a small number of patients. Since there are not too many studies on this topic, they believe that their study will contribute to the determination of place and role of this treatment approach.

scholarly journals Evaluation of the effectiveness of personalized complex therapy in patients with benign prostatic hyperplasia and chronic prostatitis

2021 ◽  
Vol 11 (1) ◽  
pp. 39-48
Author(s):  
Ivan I. Barannikov ◽  
Andrey V. Kuzmenko ◽  
Timur А. Gyaurgiev ◽  
Vladimir V. Kuzmenko
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Chronic Prostatitis ◽  
Lower Urinary Tract ◽  
Prostatic Hyperplasia ◽  
Bacteriological Examination ◽  
Hemodynamic Parameters ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

PURPOSE OF THE STUDY: to evaluate the effectiveness of personalized complex treatment of patients with benign prostatic hyperplasia (BPH) in combination with chronic prostatitis using a combined physiotherapeutic effect, taking into account the individual chronobiological characteristics of patients. MATERIALS AND METHODS: We examined 60 patients with benign prostatic hyperplasia and chronic prostatitis who were sent to the TUR of the prostate. Patients were divided into two groups (n = 30). The comparison group (CG) was treated with alpha-blockers and fluoroquinolones for 28 days. In the main group (MG) personalized complex therapy. The effectiveness of treatment was evaluated at the time of treatment (visit 1), two weeks later (visit 2) and 4 weeks later (visit 3). The severity of lower urinary tract symptoms, prostate volume and residual urine volume, hemodynamic parameters in the gland were evaluated, and a bacterioscopic and bacteriological examination of prostate secretion was performed. RESULTS: At the end of 4 weeks of therapy, statistically significant differences (p 0.05) were found in the MG for all the studied parameters. In the bacteriological study of prostate secretions at visit 1 Escherichia coli prevailed in the crops. At visit 2 to the CG bacteria were detected in 11 (36.7%) crops, and in 10 (33.3%) patients in the MG. At visit 3, no microbial growth was detected in both groups based on the results of a bacteriological examination of prostate secretions. Initially, both groups had low hemodynamic parameters in the prostate. After the treatment, a more pronounced dynamics of improvement of blood flow in the gland by visit 2 was noted in the MG than in the GP. By visit 3, statistically significant differences were found in all the studied indicators (p 0.05). CONCLUSION: Thus, according to the results, a personalized comprehensive treatment of patients with benign prostatic hyperplasia and chronic prostatitis reduced the severity of lower urinary tract symptoms and manifestations of the inflammatory process in the prostate, improved hemodynamic parameters and increase of efficiency of antibacterial therapy, as evidenced by the results of bacteriological studies. PURPOSE OF THE STUDY: to evaluate the effectiveness of personalized complex treatment of patients with benign prostatic hyperplasia (BPH) in combination with chronic prostatitis using a combined physiotherapeutic effect, taking into account the individual chronobiological characteristics of patients. MATERIALS AND METHODS: We examined 60 patients with benign prostatic hyperplasia and chronic prostatitis who were sent to the TUR of the prostate. Patients were divided into two groups (n = 30). The comparison group (CG) was treated with alpha-blockers and fluoroquinolones for 28 days. In the main group (MG) personalized complex therapy. The effectiveness of treatment was evaluated at the time of treatment (visit 1), two weeks later (visit 2) and 4 weeks later (visit 3). The severity of lower urinary tract symptoms, prostate volume and residual urine volume, hemodynamic parameters in the gland were evaluated, and a bacterioscopic and bacteriological examination of prostate secretion was performed. RESULTS: At the end of 4 weeks of therapy, statistically significant differences (p 0.05) were found in the MG for all the studied parameters. In the bacteriological study of prostate secretions at visit 1 Escherichia coli prevailed in the crops. At visit 2 to the CG bacteria were detected in 11 (36.7%) crops, and in 10 (33.3%) patients in the MG. At visit 3, no microbial growth was detected in both groups based on the results of a bacteriological examination of prostate secretions. Initially, both groups had low hemodynamic parameters in the prostate. After the treatment, a more pronounced dynamics of improvement of blood flow in the gland by visit 2 was noted in the MG than in the GP. By visit 3, statistically significant differences were found in all the studied indicators (p 0.05). CONCLUSION: Thus, according to the results, a personalized comprehensive treatment of patients with benign prostatic hyperplasia and chronic prostatitis reduced the severity of lower urinary tract symptoms and manifestations of the inflammatory process in the prostate, improved hemodynamic parameters and increase of efficiency of antibacterial therapy, as evidenced by the results of bacteriological studies.

Sign in / Sign up

Export Citation Format

Share Document